Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
Show more
Type
Public
HQ
South San Francisco, US
Founded
1997
Size (employees)
127 (est)
Cytokinetics was founded in 1997 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Cytokinetics

Robert Blum

Robert Blum

President and Chief Executive Officer
Daniel Casper

Daniel Casper

VP, Information Technology
Bonnie Charpentier

Bonnie Charpentier

SVP, Regulatory Affairs and Compliance
Bettina Cockroft

Bettina Cockroft

VP, Clinical Research, Neurology
David Cragg

David Cragg

SVP, Human Resources
Ching Jaw

Ching Jaw

SVP, Chief Financial Officer
Show more

Cytokinetics Office Locations

Cytokinetics has an office in South San Francisco
South San Francisco, US (HQ)
280 E Grand Ave
Show all (1)
Report incorrect company information

Cytokinetics Financials and Metrics

Cytokinetics Financials

Cytokinetics's revenue was reported to be $13.37 m in FY, 2017
USD

Revenue (FY, 2017)

13.4 m

Net income (FY, 2017)

(127.8 m)

EBIT (FY, 2017)

(113.4 m)

Market capitalization (20-Apr-2018)

353.2 m

Cash (31-Dec-2017)

125.2 m

EV

259.8 m
Cytokinetics's current market capitalization is $353.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

30.6 m46.9 m28.7 m106.4 m13.4 m

Revenue growth, %

53%(39%)271%

General and administrative expense

15.1 m27.8 m36.5 m

R&D expense

49.5 m59.9 m90.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

8 m7.8 m9.4 m4.4 m6.5 m7.9 m8.4 m5.8 m59 m4.2 m3.1 m

General and administrative expense

4.3 m4.5 m4 m4.4 m4.5 m5.3 m6.8 m7.1 m7.2 m8.1 m8.4 m

R&D expense

12.5 m11.7 m11.4 m9 m12.6 m11.6 m13.5 m9.7 m19.3 m19.3 m19.8 m

Operating expense total

16.7 m16.2 m15.4 m13.3 m17.1 m16.8 m20.4 m16.8 m26.6 m27.4 m28.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

20.2 m20.2 m65.1 m66.9 m125.2 m

Accounts Receivable

1.1 m

Inventories

Current Assets

79.3 m131.1 m113.1 m158.6 m274.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

13.3 m12.4 m12.9 m22.5 m24.8 m26 m42.3 m27.7 m30.3 m49.4 m100.7 m

Accounts Receivable

24 k

Current Assets

86.1 m80.1 m81.5 m110.8 m107.9 m100.5 m106.1 m96.6 m148.2 m211 m317 m

PP&E

1.5 m1.5 m1.5 m1.6 m1.6 m1.5 m1.8 m1.7 m2 m3.5 m3.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(33.7 m)(14.6 m)(37.5 m)16.5 m(127.8 m)

Inventories

Accounts Payable

1.7 m(2.2 m)755 k1.7 m1.5 m

Cash From Operating Activities

(7.7 m)(44.8 m)4.9 m37 m(101.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.7 m)(8.4 m)(6 m)(8.9 m)(10.6 m)(8.8 m)(12.5 m)(11.6 m)31.9 m(25.9 m)

Accounts Payable

1.8 m985 k1.6 m1.4 m1.6 m1.9 m547 k2.8 m668 k3 m
USDY, 2017

EV/EBIT

-2.3 x

EV/CFO

-2.6 x

Revenue/Employee

105.3 k

Financial Leverage

2.7 x
Show all financial metrics
Report incorrect company information